| 研究課題/領域番号 |
22K14742
|
|---|
| 研究機関 | 長崎大学 |
|---|
研究代表者 |
|
|---|
| 研究期間 (年度) |
2022-04-01 – 2026-03-31
|
| キーワード | nanodrugs / metallic cluster / reprecipitation / crystallization / cancer therapy |
|---|
| 研究実績の概要 |
The purpose of this research is to design and fabricate a carrier-free nanodrug via templated-crystallization method using SN-38, the active metabolite of irinotecan, acts as a potent inhibitor of DNA topoisomerase I. In this work, several derivatives of SN-38 were selected as the anticancer moiety, and Au cluster of ca. 10 nm was selected as a template. The nanodrugs are fabricated by reprecipitation method. The modified Au/SN38-Chol nanoparticles were successfully fabricated in several sizes by adjusting the reprecipitation conditions. The existence of Au in the nanodrugs was confirmed in the UV-Vis spectra with visible absorbance at ca. 550 nm. The formation yield of the hybrid nanodrugs were suggested to be affected by the hydrophilicity of Au surface.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
1: 当初の計画以上に進展している
理由
The first target of the research plan, including establishing the fabrication method for each component of the hybrid nanodrugs and the combination into a single nanoparticle, are close to complete. The research is progressing to the optimization of the nanodrug’s morphologies and compositions, and the correlation between that and drug release is carried out in parallel.
|
| 今後の研究の推進方策 |
The next targets of the research are investigation of drug release under photothermal effect of the obtained nanodrugs, and their in vitro cytotoxicity.
|
| 次年度使用額が生じた理由 |
Due to changing of research location, several instruments that are required in the later part of the research plan became unavailable at the new location. Therefore, a part of the budget was transferred in order to obtain new instruments.
|
